Tranexamic Acid Linked to Increased Mortality Risk in Severe TBI medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Highlights
When determining whether kidneys are suitable for transplantation in the United States, biopsy analyses don t provide useful information beyond standard donor and recipient characteristics.
Many kidneys discarded based on biopsy findings would likely benefit U.S. patients who are waiting for a transplant.
Washington, DC (December 15, 2020) New research indicates that analyses of kidney biopsies from deceased donors don t provide meaningful information beyond standard assessments of donor and recipient characteristics. In addition, the study revealed that relying on these analyses has prompted the discard of many potentially suitable organs for transplantation in the United States. The findings appear in an upcoming issue of
Accounting for recent population aging is critical for estimating non-COVID-19 excess deaths in the U.S.
Estimates of excess mortality during the coronavirus disease 2019 (COVID-19) pandemic provide an important metric for quantifying deaths due to COVID-19 as well as those indirectly caused by COVID-
19. To evaluate the excess deaths in 2020 without consideration of changes to the underlying population structure can result in overestimated excess deaths. The growth of the U.S. population, particularly in older age groups, means a higher expected number of deaths in 2020 from all causes, even in the absence of COVID-19.
Researchers from the National Cancer Institute used data from the CDC National Center for Health Statistics and the U.S. Census Bureau to estimate excess mortality in the period March through August 2020. By accounting for the recent aging of the population, they found the number of excess non-COVID-19 deaths was 44,600, which is 65 percent fewer than estimated
University of Pennsylvania
Benjamin Garcia, PhD, has been named head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. His appointment is scheduled to begin July 1.
Benjamin A. Garcia, PhD, a noted leader in the field of biochemistry, especially for his work advancing mass spectrometry techniques, has been named head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. Garcia, whose appointment tentatively is set to begin July 1, also will become the Raymond H. Wittcoff Distinguished Professor.
The school’s Department of Biochemistry and Molecular Biophysics has an illustrious history as home to some of the nation’s most distinguished scientists, including scientific innovator Roy Vagelos, who headed the department then called the Department of Biological Chemistry from 1966-75 and went on to lead the development of cholesterol-lowering statin